Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market Size, Clinical Trials, Product Pipelines and Investment Trends, till 2032

Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market Size is estimated to be $8250 million in 2024 and is expected to grow at an average yearly rate of around 3.5% during the timeframe (2025-2032).

What is Direct-Acting Antiviral (DAA) Therapies for Hepatitis C and what are the growth drivers of Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market?



Direct-Acting Antiviral (DAA) therapies represent a revolutionary advancement in the treatment of chronic Hepatitis C virus (HCV) infection. Unlike older interferon-based therapies, DAAs target specific steps in the HCV replication cycle, inhibiting viral proteins such as NS3/4A protease, NS5A, and NS5B polymerase. By directly blocking these essential viral enzymes, DAAs achieve high cure rates, often exceeding 95%, with shorter treatment durations and fewer side effects. DAAs are generally administered orally and are well tolerated, making them the current gold standard for HCV treatment.

Growth Drivers of the Direct-Acting Antiviral Therapies Market

The market for DAA therapies has seen robust growth driven by several important factors. First, the global burden of chronic HCV infection remains significant, affecting millions of people and pushing governments and healthcare systems to adopt aggressive elimination targets. The World Health Organization's call to eradicate HCV by 2030 has spurred large-scale screening and treatment initiatives, boosting demand for DAAs.

Second, the clinical superiority of DAAs over traditional treatments continues to drive their market adoption. The high sustained virologic response rates, reduced side effects, and simplified regimens translate to better patient compliance and outcomes. This has created a strong preference among physicians and patients for DAA-based therapies.

Third, growing awareness of hepatitis C and the availability of generic DAAs in low- and middle-income countries have expanded access to treatment, further stimulating the market. Partnerships between pharmaceutical companies, non-profit organizations, and governments have made these therapies more affordable, broadening their reach to underserved populations.

Additionally, ongoing research and development activities continue to improve DAA therapies. Newer combinations with pangenotypic coverage are reducing the need for genotype testing and are simplifying treatment protocols even further. This innovation is attracting investment and ensuring that DAAs remain at the forefront of HCV management.

Moreover, favorable reimbursement policies and support programs are encouraging more patients to seek treatment. In high-income countries, insurance coverage and national health schemes are facilitating access, while in developing regions, price negotiations and licensing agreements are helping to make DAAs accessible to a broader population base.

Lastly, the increasing focus on harm-reduction strategies for people who inject drugs, a major at-risk population for HCV, is driving diagnosis and treatment uptake. Screening initiatives integrated into addiction treatment centers and prison health systems are identifying previously undiagnosed individuals, expanding the treated population, and thereby strengthening demand for DAAs.

The research and analytics firm Datavagyanik released the updated version of its report on "Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market - Detailed Analysis, Business Opportunities and Forecasts".

Request sample at https://datavagyanik.com/reports/direct-acting-antiviral-daa-therapies-for-hepatitis-c-market/



Clinical Trials in Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market and New Product Pipelines

Clinical trials have played a critical role in transforming the treatment landscape of hepatitis C through the development of direct-acting antiviral therapies. These trials focus on testing the safety, efficacy, and tolerability of new drug candidates and combination regimens. Recent studies have moved beyond proving high cure rates and are now exploring shorter treatment durations, pangenotypic activity, and improved outcomes in special populations such as children, patients with cirrhosis, and those with co-infections like HIV. Adaptive trial designs are also being used to optimize therapy lengths, explore response-guided treatments, and minimize resistance development. Furthermore, many trials are incorporating real-world populations with comorbidities and advanced liver disease to ensure that treatment effectiveness translates outside controlled settings. The emphasis on simplified, once-daily, oral regimens with fewer side effects has greatly increased patient compliance, which is a central objective of these clinical programs.

Advancements in Special Population Studies

A significant focus of ongoing trials is the evaluation of direct-acting antivirals in pediatric populations and in individuals with acute HCV infection. Traditionally, chronic hepatitis C therapy was limited to adults, but recent trials have expanded the eligibility to children as young as three years old, demonstrating comparable safety and high sustained virologic response rates. Trials in acute infection are also showing that DAAs can be highly effective at curing hepatitis C before it progresses to chronic disease, reducing the risk of long-term complications such as cirrhosis or hepatocellular carcinoma. Additionally, studies are underway to address hard-to-treat populations, including those with previous DAA treatment failures or those with advanced cirrhosis, using next-generation regimens with improved resistance profiles.

New Product Pipelines in Direct-Acting Antiviral Therapies

The product pipeline for direct-acting antivirals continues to expand with promising candidates entering advanced phases of clinical development. New combinations are being designed to achieve higher cure rates in shorter durations, sometimes as brief as six to eight weeks. Pangenotypic regimens, which can treat all major genotypes of hepatitis C, are a key focus area to simplify treatment and avoid the need for genotyping, particularly in resource-limited settings. Compounds targeting novel viral proteins, or combining existing NS5A, NS3/4A, and NS5B inhibitors in innovative ways, are demonstrating strong potential in clinical trials. Some newer regimens are specifically formulated to reduce drug-drug interactions, making them safer for patients with multiple comorbidities or those taking other chronic medications.




Request for customization https://datavagyanik.com/reports/direct-acting-antiviral-daa-therapies-for-hepatitis-c-market/




Important target segments driving the demand for Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market

The demand for direct-acting antiviral therapies for hepatitis C is driven by several important patient segments that play a vital role in expanding the market. As hepatitis C affects a diverse population, identifying and prioritizing these groups helps guide treatment programs and public health strategies. High-risk populations, underserved communities, and individuals with advanced disease contribute significantly to the growing need for effective and accessible DAA therapies.

People with Chronic Hepatitis C Infection

The largest and most crucial segment includes individuals living with chronic hepatitis C infection. Millions of people worldwide suffer from chronic hepatitis C, many of whom were diagnosed years ago and did not have access to curative treatment options. With DAAs offering high cure rates and excellent safety profiles, there is strong demand among this population for effective therapy that can prevent disease progression, cirrhosis, liver failure, and liver cancer. Treating these chronically infected patients remains a cornerstone of the DAA market.

People Who Inject Drugs

Another essential target segment consists of people who inject drugs. This group is at high risk of acquiring hepatitis C due to needle-sharing practices and generally experiences higher infection rates than the general population. Expanding treatment access for this segment is critical not only for their own health but also for preventing further transmission in the community. Harm-reduction programs, needle-exchange sites, and addiction treatment centers have become key locations for identifying and treating people who inject drugs, fueling demand for DAAs.

Prison Populations

Incarcerated individuals represent another important segment for DAA therapies. Hepatitis C prevalence in prison populations is far higher than in the general community due to factors such as previous injection drug use and limited access to preventive care. Correctional facilities worldwide have increasingly prioritized screening and treatment for hepatitis C, driving the demand for short-duration, easy-to-administer, and highly effective DAA regimens that can be completed during a typical period of incarceration.

Patients with Advanced Liver Disease

People living with advanced liver disease, including cirrhosis or compensated liver failure, are a significant driver of DAA demand. These patients face a much higher risk of developing liver cancer and experiencing severe complications from chronic hepatitis C. DAAs provide a lifeline for this group, preventing disease progression and often improving liver function. As healthcare systems shift their focus to reducing the burden of liver-related mortality, these patients remain a high-priority treatment population.

Co-infected Patients

Individuals who are co-infected with HIV and hepatitis C form another critical segment for DAA therapies. Co-infection accelerates liver disease progression and complicates management, making rapid and effective treatment essential. DAAs have been shown to work well in co-infected patients, encouraging healthcare providers to target this vulnerable group for priority treatment.



Key Players in Direct-Acting Antiviral (DAA) Therapies for Hepatitis C, Market Share

The market for direct-acting antiviral therapies for hepatitis C is dominated by a handful of major pharmaceutical companies that have developed highly effective and widely adopted treatment regimens. These industry leaders have invested significantly in research and development, clinical trials, and global access initiatives, enabling them to build a strong market presence and maintain high market shares. Their products have become the backbone of hepatitis C treatment across most regions of the world.

Gilead Sciences

Gilead Sciences is one of the most prominent players in the DAA market, largely due to its blockbuster drugs sofosbuvir-based combinations such as sofosbuvir/ledipasvir and sofosbuvir/velpatasvir. These regimens offer pangenotypic coverage, short treatment durations, and high cure rates, earning widespread adoption globally. Gilead has leveraged strategic pricing, generic licensing, and partnerships in low- and middle-income countries to expand its reach, which has secured it a leading share of the DAA market.

AbbVie

AbbVie has also secured a strong position in the hepatitis C antiviral market through its glecaprevir/pibrentasvir combination, which is marketed as an affordable, highly effective pangenotypic regimen. This treatment has been praised for its shorter treatment course of eight weeks for many patients and its excellent safety profile. AbbVie's proactive marketing strategies and efforts to address treatment in special populations, including those with renal impairment, have further solidified its market share.

Merck & Co.

Merck has contributed to the DAA landscape with its grazoprevir/elbasvir regimen, offering an effective option for genotype-specific treatment with particular benefits for patients co-infected with HIV. Though Merck holds a smaller market share compared to Gilead and AbbVie, its product portfolio is an important part of the overall market landscape and is valued for its niche applications and support for specific patient groups.

Bristol Myers Squibb

Bristol Myers Squibb, one of the early pioneers in DAA development, marketed daclatasvir in combination with sofosbuvir, delivering an effective pangenotypic option in many regions. Although its market presence is more limited today due to competitive pressures and shifting guidelines, the company remains an important contributor to hepatitis C care in certain countries and continues to hold a share of the market through regional partnerships and licensing deals.

Emerging Players and Generics

Beyond these established leaders, a growing wave of generic manufacturers and regional pharmaceutical companies is shaping the competitive environment. Generic versions of sofosbuvir, daclatasvir, and other DAAs have dramatically increased treatment access in low- and middle-income countries. These companies are gaining market share by offering affordable alternatives that meet World Health Organization prequalification standards. As governments strive to meet hepatitis C elimination targets, generics will continue to play a critical role in expanding treatment reach and driving down overall costs.



Key Questions Answered in the Direct-Acting Antiviral (DAA) Therapies for Hepatitis C market report:

What is the total global Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Sales, and how has it changed over the past five years?

What is Direct-Acting Antiviral (DAA) Therapies for Hepatitis C investment trend?

Which countries have the highest Direct-Acting Antiviral (DAA) Therapies for Hepatitis C, and what factors contribute to their dominance in the market?

How does Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Sales vary across key manufacturers, and what expansions have been observed recently?

What is the current global revenue generated from Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Sales, and how does it compare to previous years?

Which industries drive the highest demand for Direct-Acting Antiviral (DAA) Therapies for Hepatitis C, and how is this demand expected to evolve in the next five years?

What are the major challenges impacting Direct-Acting Antiviral (DAA) Therapies for Hepatitis C industry and supply chain operations across key markets?

How do government policies, environmental regulations, and trade restrictions affect Direct-Acting Antiviral (DAA) Therapies for Hepatitis C and market dynamics?

Related Studies:

Hormonal (Endocrine) Therapies for Breast Adenocarcinoma Market
https://datavagyanik.com/reports/hormonal-endocrine-therapies-for-breast-adenocarcinoma-market/

PARP Inhibitors for Breast Adenocarcinoma Market
https://datavagyanik.com/reports/parp-inhibitors-for-breast-adenocarcinoma-market/

Sphingosine 1-Phosphate (S1P) Receptor Modulators Market
https://datavagyanik.com/reports/sphingosine-1-phosphate-s1p-receptor-modulators-market/

Corticosteroids for Crohn's Disease Market
https://datavagyanik.com/reports/corticosteroids-for-crohns-disease-market/

Janus Kinase (JAK) Inhibitors for Crohn's Disease Market
https://datavagyanik.com/reports/janus-kinase-jak-inhibitors-for-crohns-disease-market/

IT Park, Dehradun, UK

Datavagyanik is a business intelligence firm with clients worldwide. We provide the right knowledge and advisory to business organizations and help them to grow and excel. We specialize in areas such as Pharmaceutical, Healthcare, Manufacturing, Consumer Goods, Materials & Chemicals and others. We specialize in market sizing, forecasting, supply chain analysis, supplier intelligence, import-export insights, market trend analysis and competitive intelligence.

Contact us:

Peter (Sales Head)
Phone: +1-330-440-0311
Website: https://datavagyanik.com/
Linkedin: https://www.linkedin.com/company/datavagyanik-business-intelligence-solutions/
Email: sales@datavagyanik.com

This release was published on openPR.